WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines.
Updated risk rates for hospital admission in patients with non-severe COVID-19
The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19.
The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients.
This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines:
**High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%.
**Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%.
Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk.
Review of COVID-19 treatments for people with non-severe COVID-19
WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022.
If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead.
WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission.
For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol.
WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials.
The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials.
more
SODIS manual - updated version
The SODIS manual contains detailed information about technical and promotional aspects of the SODIS method.
Former version also available in French, Portuguese, Spanish, Uzbek, Russian
Essential Medicines are those that satisfy the priority health care needs of the population. They are selected with due regard to public health relevance, evidence on efficacy, safety and comparative cost-effectiveness. This edition of the Essential Medicines List (EML) 2017 for Ghana has been deriv...ed from its companion Standard Treatment Guidelines 2017 to ensure harmony in treatment, procurement and re-imbursements. The medicines listed have been coded according to the Health Commodity
Codes Catalogue of the Ministry of Health (2008) and their levels of use, based on the type of health facility, including midwifery practice, have been indicated.
more
A guide for civil society
Accessed: 30.01.2020
Indonesian Prevention Guidelines on HIV and AIDS
6th edition, 2010. | Published in collaboration with World Health Organisation and Clinton Health Access Initiative.
The objective of this project was to list the medical devices required to provide the essential reproductive, maternal, newborn and child health interventions defined by existing WHO guidelines and publications, in order to improve access to these devices in low- and middle-income countries, support... quality of care, and strengthen health-care system. The medical devices are allocated across the reproductive, maternal, newborn and child health continuum of care according to the level of health-care delivery.
more
The new WHO Guidelines on Sanitation and Health summarize the evidence on the effectiveness of a range of sanitation interventions and provide a comprehensive framework for health-protecting sanitation, covering policy and governance measures, implementation of sanitation technologies, systems and b...ehavioural interventions, risk-based management, and monitoring approaches. Critically, the guidelines articulate the role of the health sector in maximizing the health impact of sanitation interventions.
The guidelines also identify gaps in the evidence-base to guide future research efforts to improve the effectiveness of sanitation interventions.
(French, Spanish, Russian, Arabic in production)
more
Transforming Health: Accelerating attainment of Health Goals | THE SECOND MEDIUM TERM PLAN FOR HEALTH
Diagnosis and Management of Systemic Lupus Erythematosus
Key populations brief
Accessed November 2017
Waste Management & Research 39(1) DOI: 10.1177/0734242X211029175
La Región de las Américas constituye un territorio extremadamente rico desde el punto de vista de la diversidad cultural, en la cual se presentan una variedad de desafíos relacionados con el reconocimiento y el respeto de los derechos humanos de los miembros de los pueblos indígenas, los afrodes...cendientes, los romaníes, así como de otros grupos étnicos. A lo largo del curso de la vida, estas personas experimentan discriminación estructural y poca representatividad e inclusión en los procesos de toma de decisiones, lo cual dificulta su acceso a los servicios de salud, afecta la calidad de la atención que reciben y tiene un efecto general en sus condiciones de vida. Por tanto, la protección y la promoción de su salud y seguridad socioeconómica es una cuestión no solo de política pública, sino también de protección y ejercicio de los derechos humanos. En esta publicación se presentan los instrumentos internacionales y regionales de derechos humanos y los sistemas de protección de esos derechos instaurados por las Naciones Unidas y el Sistema Interamericano de Derechos Humanos, así como medidas para hacerlos efectivos, con especial hincapié en el derecho a la salud, al medio ambiente sano y otros derechos relacionados con el cuidado del planeta.
more
Blueprint for EECA countries, first edition